EUVIMEDEUVIMED entdecken
Crossref

Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15

Athénaïs Boucly, Stéphane Mitrovic, Maryvonnick Carmagnat, Laurent Savale, Xavier Jaïs, Jean-Luc Taupin, Estibaliz Lazaro, Emilie Berthoux, Nicolas Schleinitz, Maria-Rosa Ghigna, Joanna Kedra, Xavier Mariette und 6 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.04.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Athénaïs Boucly und 17 weiteren Autor:innen. Beteiligte Einrichtung: APHP, Hôpital Bicêtre, DMU Thorinno, Service de Pneumologie, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bic…. Hauptthemen laut MEDLINE: HLA-DRB1 Chains, Pulmonary Arterial Hypertension, Still's Disease, Adult-Onset, Hypertension, Pulmonary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Inflammatory lung disease in Still's disease (SD) has recently been described. Among its manifestations, pulmonary arterial hypertension (PAH) is a rare and life-threatening event, with only a few case reports published. The objective was to report the largest adult cohort of PAH occurring in the context of SD. METHODS: We identified 16 adult SD patients with PAH (PAH+) by a call for observations from the CRI-IMIDIATE (Club Rhumatismes & Inflammation - Immune-Mediated Inflammatory Disease Alliance for Translational and Clinical Research) network (https://cri-net.com/recherche/reseau-CRI-Imidiate/) and a search of the French pulmonary hypertension network registry. Patient characteristics and disease evolution were retrospectively compared with those of 111 SD controls without PAH (PAH-) followed in a reference centre. RESULTS: The profile of patients in the PAH+ and PAH- groups differed: 100% versus 69.4% female (P = .006), 75% versus 17.1% Black (P < .0001), more active SD both at diagnosis and throughout the disease course, and more likely to present macrophage activation syndrome (62.5% vs 14.4%, P < .0001) and exhibit eosinophilia during the disease course (68.7% vs 7.2%, P < .0001). For the 84 out of 127 patients with genetic typing, the HLA-DRB1*15 allele was more prevalent in PAH+ than PAH- patients (8/11 [72.7%] vs 22/73 [30.1%], P = .014). PAH+ patients more frequently received canakinumab and immunosuppressants than did PAH- patients and had higher frequency of drug reactions to interleukin 1 (IL-1) and/or IL-6 inhibitors (37.5% vs 7.2%, P = .002). Mortality was higher in PAH+ than PAH- patients (37.5% vs 0.9%, P < .0001), and all deaths were related to SD flare. CONCLUSIONS: These results reinforce the association between the HLA-DRB1*15 allele and severe forms of SD and raise the question of therapeutic optimisation in such patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-DRB1 ChainsPulmonary Arterial HypertensionStill's Disease, Adult-OnsetHypertension, PulmonaryHumansFemaleMaleAdultMiddle AgedRetrospective StudiesAgedAntibodies, Monoclonal, HumanizedMacrophage Activation Syndrome

Substanzen

HLA-DRB1 ChainsHLA-DRB1*15 antigenAntibodies, Monoclonal, Humanizedcanakinumab

Autor:innen und Institutionen

  • APHP, Hôpital Bicêtre, DMU Thorinno, Service de Pneumologie, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM, UMR S_999, Le Kremlin-Bicêtre, France.
  • Sorbonne Université-APHP, Service de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, France; Centre d'Etude et de Référence sur les Maladies AutoInflammatoires et les Amyloses (CEREMAIA), FAI2R network, Paris, France; I…
  • Hôpital Saint Louis, APHP, Laboratoire d'Immunologie et Histocompatibilité, Paris, France.
  • Hôpital Haut-Lévêque, service de Médecine Interne, CHU Bordeaux, France.
  • Hôpital Saint Joseph-Saint Luc, service de Médecine Interne, Lyon, France.
  • Hôpital de la Timone, AP-HM, Département de Médecine Interne, Aix-Marseille Université, Marseille, France.

Zitieren

APA

Boucly, A., Mitrovic, S., Carmagnat, M., Savale, L., Jaïs, X., Taupin, J. L., Lazaro, E., Berthoux, E., Schleinitz, N., Ghigna, M. R., Kedra, J., Mariette, X., Roussin, C., Juge, P. A., Humbert, M., Sitbon, O., Montani, D., & Fautrel, B. (2025). Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.04.016

Vancouver

Boucly A, Mitrovic S, Carmagnat M, Savale L, Jaïs X, Taupin JL, et al. Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.04.016

BibTeX
@article{Boucly2025,
  author = {Boucly, Athénaïs and Mitrovic, Stéphane and Carmagnat, Maryvonnick and Savale, Laurent and Jaïs, Xavier and Taupin, Jean-Luc and Lazaro, Estibaliz and Berthoux, Emilie and Schleinitz, Nicolas and Ghigna, Maria-Rosa and Kedra, Joanna and Mariette, Xavier and Roussin, Céline and Juge, Pierre-Antoine and Humbert, Marc and Sitbon, Olivier and Montani, David and Fautrel, Bruno},
  title = {Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.04.016}
}
Kostenlos starten →